Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 1
1983 1
1985 3
1987 1
1988 2
1989 2
1991 3
1992 4
1993 6
1994 8
1995 9
1996 8
1997 5
1998 7
1999 5
2000 2
2001 6
2002 5
2003 6
2004 13
2005 12
2006 5
2007 5
2008 19
2009 18
2010 13
2011 25
2012 28
2013 29
2014 35
2015 29
2016 34
2017 41
2018 28
2019 33
2020 42
2021 40
2022 26
Text availability
Article attribute
Article type
Publication date

Search Results

490 results
Results by year
Filters applied: . Clear all
Page 1
EAU-EANM Consensus Statements on the Role of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Patients with Prostate Cancer and with Respect to [177Lu]Lu-PSMA Radioligand Therapy.
Fanti S, Briganti A, Emmett L, Fizazi K, Gillessen S, Goffin K, Hadaschik BA, Herrmann K, Kunikowska J, Maurer T, MacLennan S, Mottet N, Murphy DG, Oprea-Lager DE, O'Sullivan JM, Oyen WJG, Rouvière O, Sartor O, Stenzl A, Van Poppel H, Walz J, Witjes W, Bjartell A. Fanti S, et al. Among authors: sartor o. Eur Urol Oncol. 2022 Jun 10:S2588-9311(22)00086-4. doi: 10.1016/j.euo.2022.05.003. Online ahead of print. Eur Urol Oncol. 2022. PMID: 35697600 Free article.
Neutropenia, neutrophilia, and neutrophil-lymphocyte ratio as prognostic markers in patients with metastatic castration-resistant prostate cancer.
Meisel A, de Wit R, Oudard S, Sartor O, Stenner-Liewen F, Shun Z, Foster M, Ozatilgan A, Eisenberger M, de Bono JS. Meisel A, et al. Among authors: sartor o. Ther Adv Med Oncol. 2022 Jun 1;14:17588359221100022. doi: 10.1177/17588359221100022. eCollection 2022. Ther Adv Med Oncol. 2022. PMID: 35677318 Free PMC article.
The Influence of the Pretreatment Immune State on Response to Radiation Therapy in High Risk Prostate Cancer: A Validation Study from NRG/RTOG 0521.
Hall WA, Karrison TG, Rosenthal SA, Amin MB, Gomella LG, Purdy JA, Sartor AO, Michalski JM, Garzotto MG, Bergom CR, Jani AB, Lawton CAF, Simko JP, Moore JK, Gore EM, Lee WR, Nguyen PL, Danielson BL, Sandler HM, Feng FY. Hall WA, et al. Among authors: sartor ao. Int J Radiat Oncol Biol Phys. 2022 Jun 5:S0360-3016(22)00555-7. doi: 10.1016/j.ijrobp.2022.05.048. Online ahead of print. Int J Radiat Oncol Biol Phys. 2022. PMID: 35675855
The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial.
Pollack A, Karrison TG, Balogh AG, Gomella LG, Low DA, Bruner DW, Wefel JS, Martin AG, Michalski JM, Angyalfi SJ, Lukka H, Faria SL, Rodrigues GB, Beauchemin MC, Lee RJ, Seaward SA, Allen AM, Monitto DC, Seiferheld W, Sartor O, Feng F, Sandler HM. Pollack A, et al. Among authors: sartor o. Lancet. 2022 May 14;399(10338):1886-1901. doi: 10.1016/S0140-6736(21)01790-6. Lancet. 2022. PMID: 35569466 Clinical Trial.
Interim analysis of companion, prospective, phase II, clinical trials assessing the efficacy and safety of multi-modal total eradication therapy in men with synchronous oligometastatic prostate cancer.
Reyes DK, Trock BJ, Tran PT, Pavlovich CP, Deville C, Allaf ME, Greco SC, Song DY, Bivalacqua TJ, Han M, Partin AW, Sartor AO, Rowe SP, Pienta KJ. Reyes DK, et al. Among authors: sartor ao. Med Oncol. 2022 Apr 28;39(5):63. doi: 10.1007/s12032-022-01662-7. Med Oncol. 2022. PMID: 35478055 Clinical Trial.
490 results